Jasper Therapeutics, Inc. JSPR
are a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous
Urticaria ("CSU"), Chronic Inducible Urticaria ("CIndU") and asthma and we continue to consider additional indications
in mast cell driven diseases for potential future development. We have also historically explored development programs in diseases where
targeting diseased hemopoietic stem cells can provide benefits, such as stem cell transplant conditioning regimens, but those programs
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cost of revenue | $41.6M | $34.3M | — | — | — | — | — |
| R&D | $63.1M | $55.8M | $51.8M | $34.6M | $25.4M | $15.9M | — |
| SG&A | $20.8M | $20.4M | $17.1M | $16.6M | $11.4M | $4.8M | — |
| Total operating expenses | $83.9M | $76.2M | $68.9M | $51.2M | $36.8M | $20.7M | — |
| Operating income | -$83.9M | -$76.2M | -$68.9M | -$51.2M | $2.9M | -$20.7M | $2.9M |
| Interest expense | — | — | $246.0K | $115.0K | $80.0K | $111.0K | — |
| Pre-tax income | — | -$71.3M | -$64.5M | — | — | -$6.4M | — |
| Income tax | — | $2.0K | $2.0K | — | — | $38.5K | — |
| Net income | -$76 | -$71.3M | -$64.5M | -$37.7M | -$30.6M | -$31.7M | — |
| EPS, basic | -3.95 | -4.89 | -6.18 | -10.33 | -2.69 | — | — |
| EPS, diluted | -3.95 | -4.89 | -6.18 | -10.33 | -2.69 | -5.17 | — |
| Shares, diluted (wtd. avg.) | $19.2M | $14.6M | $10.4M | $3.6M | $11.4M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $28.7M | $71.6M | $87.3M | $38.7M | $85.0M | $20.2M | $27.2M |
| Total current assets | $34.6M | $75.8M | $88.9M | $41.7M | $87.8M | $20.7M | $1.5M |
| Property, plant and equipment | $102.0K | $1.9M | $2.7M | $3.6M | $3.7M | $693.0K | — |
| Total assets | $35.8M | $79.9M | $94.9M | $48.4M | $93.7M | $23.4M | $101.7M |
| Accounts payable | $6.2M | $4.0M | $4.1M | $1.8M | $3.9M | $1.4M | $95.1K |
| Total current liabilities | $13.2M | $15.2M | $12.4M | $7.1M | $8.0M | $4.0M | $111.4K |
| Total liabilities | $31.6M | $18.2M | $16.5M | $12.4M | $24.1M | $14.6M | $10.9M |
| Retained earnings | -$316.7M | -$240.9M | -$169.6M | -$105.1M | -$67.5M | -$36.8M | -$596.4K |
| Total equity | $4.2M | $61.7M | $78.4M | $36.0M | $69.5M | -$35.1M | -$4.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$77.2M | -$62.6M | -$52.1M | -$45.9M | -$33.7M | -$18.3M | — |
| Depreciation and amortisation | — | — | $1.1M | $975.0K | — | — | — |
| Stock-based compensation | $6.7M | $6.6M | $5.2M | $4.1M | $1.0M | $1.2M | — |
| Investing cash flow | $5.0K | -$532.0K | -$267.0K | -$576.0K | -$2.4M | $198.3K | — |
| Financing cash flow | $34.2M | $47.9M | $101.0M | $55.0K | $101.0M | $11.3M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-068765.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |